Verastem | VSTM - Assets


Verastem reported $176.85M in Assets for its fiscal quarter ending in September of 2025.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Alaunos Therapeutics USD 3.72M 1.01M Sep/2025
AstraZeneca USD 114.07B 382M Dec/2025
Curis USD 29.23M 10.09M Jun/2025
Cytokinetics USD 1.42B 12.02M Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
Incyte USD 6.96B 627.62M Dec/2025
Laboratory Of America USD 18.39B 131.1M Dec/2025
Novartis USD 107.29B 2.89B Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
TG Therapeutics USD 1.06B 38.23M Dec/2025
Verastem USD 176.85M 45.15M Sep/2025